Cisplatin-docetaxel induction chemotherapy for patients with nasopharyngeal carcinoma in a non-endemic cohort

This is the report on our clinic's 15 years of experience (2004-2018) on nasopharyngeal carcinoma (NPC), treated with induction chemotherapy (IC) and subsequent concomitant chemoradiotherapy (CCRT), comprising population characteristics and treatment outcomes of 203 patients with non-metastatic...

Full description

Saved in:
Bibliographic Details
Published in:Journal of chemotherapy (Florence) 2024-04, Vol.ahead-of-print (ahead-of-print), p.1-10
Main Authors: Özkaya Toraman, Kübra, Meral, Rasim, Karadeniz, Ahmet Nafiz, Kaval, Gizem, Başaran, Mert, Ekenel, Meltem, Altun, Musa
Format: Article
Language:English
Subjects:
Antineoplastic Combined Chemotherapy Protocols - adverse effects
Chemoradiotherapy
Cisplatin
concomitant chemoradiotherapy
docetaxel
Docetaxel - therapeutic use
Humans
Induction Chemotherapy
Kaplan-Meier Estimate
Nasopharyngeal carcinoma
Nasopharyngeal Carcinoma - drug therapy
Nasopharyngeal Carcinoma - etiology
Nasopharyngeal Neoplasms - drug therapy
Nasopharyngeal Neoplasms - pathology
Retrospective Studies
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites cdi_FETCH-LOGICAL-c314t-64d9ec86c957ca866d16622f3a094bd799296ebece4c340d9d51b2faa818c7403
container_end_page 10
container_issue ahead-of-print
container_start_page 1
container_title Journal of chemotherapy (Florence)
container_volume ahead-of-print
creator Özkaya Toraman, Kübra
Meral, Rasim
Karadeniz, Ahmet Nafiz
Kaval, Gizem
Başaran, Mert
Ekenel, Meltem
Altun, Musa
description This is the report on our clinic's 15 years of experience (2004-2018) on nasopharyngeal carcinoma (NPC), treated with induction chemotherapy (IC) and subsequent concomitant chemoradiotherapy (CCRT), comprising population characteristics and treatment outcomes of 203 patients with non-metastatic NPC. IC comprised docetaxel (75 mg/m 2 ) and cisplatin (75 mg/m 2 ) combination (TP). Concurrent cisplatin (P) was applied either weekly (40 mg/m 2 , 32 cases) or every-3-week (100 mg/m 2 , 171 cases). The median follow-up duration was 85 months (range, 5-204 months). Overall and distant failure rates were observed in 27.1% (n = 55) and 13.8% (n = 28) patients, respectively. The 5-year locoregional recurrence-free survival (LRRFS), distant metastasis-free survival (DMFS), disease-free survival (DFS), and overall survival (OS) rates were 84.1%, 86.4%, 75%, and 78.7% respectively. The overall stage was an independent prognostic factor for the LRRFS, DMFS, DFS, and OS. The WHO histological type was a prognostic factor for the LRRFS, DFS, and OS. Age was a prognostic factor for the DMFS, DFS, and OS. Concurrent P schedule was independent prognostic only the LRRFS.
doi_str_mv 10.1080/1120009X.2023.2215090
format article
fullrecord <record><control><sourceid>proquest_infor</sourceid><recordid>TN_cdi_proquest_miscellaneous_2817778025</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2817778025</sourcerecordid><originalsourceid>FETCH-LOGICAL-c314t-64d9ec86c957ca866d16622f3a094bd799296ebece4c340d9d51b2faa818c7403</originalsourceid><addsrcrecordid>eNp9kMtuFDEQRS1ERKKQTwjykk1P_Oj2YwcaEUCKxAak7CyPXU0bdduN7VGYv49HM2GZVdXi3Fuqg9AtJRtKFLmjlBFC9OOGEcY3jNGBaPIGXVEtead7qd62vTHdEbpEN6X8aTwRTHIt3qFLLhmlSrArtGxDWWdbQ-x8clDtP5hxiH7vakgRuwmWVCfIdj3gMWW8NhRiLfgp1AlHW9I62XyIv8HO2NnsQkyLbQ3Y4phiB9HDEhx2aUq5vkcXo50L3JznNfp1_-Xn9lv38OPr9-3nh85x2tdO9F6DU8LpQTqrhPBUCMZGbonud15qzbSAHTjoHe-J136gOzZaq6hysif8Gn089a45_d1DqWYJxcE82whpXwxTVEqpCBsaOpxQl1MpGUaz5rC0lwwl5ijbvMg2R9nmLLvlPpxP7HcL-P-pF7UN-HQCQmziFvuU8uxNtYc55THb6EIx_PUbz4HokDg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2817778025</pqid></control><display><type>article</type><title>Cisplatin-docetaxel induction chemotherapy for patients with nasopharyngeal carcinoma in a non-endemic cohort</title><source>Taylor and Francis:Jisc Collections:Taylor and Francis Read and Publish Agreement 2024-2025:Medical Collection (Reading list)</source><creator>Özkaya Toraman, Kübra ; Meral, Rasim ; Karadeniz, Ahmet Nafiz ; Kaval, Gizem ; Başaran, Mert ; Ekenel, Meltem ; Altun, Musa</creator><creatorcontrib>Özkaya Toraman, Kübra ; Meral, Rasim ; Karadeniz, Ahmet Nafiz ; Kaval, Gizem ; Başaran, Mert ; Ekenel, Meltem ; Altun, Musa</creatorcontrib><description>This is the report on our clinic's 15 years of experience (2004-2018) on nasopharyngeal carcinoma (NPC), treated with induction chemotherapy (IC) and subsequent concomitant chemoradiotherapy (CCRT), comprising population characteristics and treatment outcomes of 203 patients with non-metastatic NPC. IC comprised docetaxel (75 mg/m 2 ) and cisplatin (75 mg/m 2 ) combination (TP). Concurrent cisplatin (P) was applied either weekly (40 mg/m 2 , 32 cases) or every-3-week (100 mg/m 2 , 171 cases). The median follow-up duration was 85 months (range, 5-204 months). Overall and distant failure rates were observed in 27.1% (n = 55) and 13.8% (n = 28) patients, respectively. The 5-year locoregional recurrence-free survival (LRRFS), distant metastasis-free survival (DMFS), disease-free survival (DFS), and overall survival (OS) rates were 84.1%, 86.4%, 75%, and 78.7% respectively. The overall stage was an independent prognostic factor for the LRRFS, DMFS, DFS, and OS. The WHO histological type was a prognostic factor for the LRRFS, DFS, and OS. Age was a prognostic factor for the DMFS, DFS, and OS. Concurrent P schedule was independent prognostic only the LRRFS.</description><identifier>ISSN: 1120-009X</identifier><identifier>EISSN: 1973-9478</identifier><identifier>DOI: 10.1080/1120009X.2023.2215090</identifier><identifier>PMID: 37211862</identifier><language>eng</language><publisher>England: Taylor &amp; Francis</publisher><subject>Antineoplastic Combined Chemotherapy Protocols - adverse effects ; Chemoradiotherapy ; Cisplatin ; concomitant chemoradiotherapy ; docetaxel ; Docetaxel - therapeutic use ; Humans ; Induction Chemotherapy ; Kaplan-Meier Estimate ; Nasopharyngeal carcinoma ; Nasopharyngeal Carcinoma - drug therapy ; Nasopharyngeal Carcinoma - etiology ; Nasopharyngeal Neoplasms - drug therapy ; Nasopharyngeal Neoplasms - pathology ; Retrospective Studies</subject><ispartof>Journal of chemotherapy (Florence), 2024-04, Vol.ahead-of-print (ahead-of-print), p.1-10</ispartof><rights>2023 Edizioni Scientifiche per l'Informazione su Farmaci e Terapia (Italian Society of Chemotherapy) 2023</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c314t-64d9ec86c957ca866d16622f3a094bd799296ebece4c340d9d51b2faa818c7403</cites><orcidid>0000-0003-0943-7287 ; 0000-0003-1887-5561 ; 0000-0003-2518-5980 ; 0000-0002-6585-4598 ; 0000-0003-1006-1942 ; 0000-0001-5437-134X ; 0000-0002-4921-6975</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37211862$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Özkaya Toraman, Kübra</creatorcontrib><creatorcontrib>Meral, Rasim</creatorcontrib><creatorcontrib>Karadeniz, Ahmet Nafiz</creatorcontrib><creatorcontrib>Kaval, Gizem</creatorcontrib><creatorcontrib>Başaran, Mert</creatorcontrib><creatorcontrib>Ekenel, Meltem</creatorcontrib><creatorcontrib>Altun, Musa</creatorcontrib><title>Cisplatin-docetaxel induction chemotherapy for patients with nasopharyngeal carcinoma in a non-endemic cohort</title><title>Journal of chemotherapy (Florence)</title><addtitle>J Chemother</addtitle><description>This is the report on our clinic's 15 years of experience (2004-2018) on nasopharyngeal carcinoma (NPC), treated with induction chemotherapy (IC) and subsequent concomitant chemoradiotherapy (CCRT), comprising population characteristics and treatment outcomes of 203 patients with non-metastatic NPC. IC comprised docetaxel (75 mg/m 2 ) and cisplatin (75 mg/m 2 ) combination (TP). Concurrent cisplatin (P) was applied either weekly (40 mg/m 2 , 32 cases) or every-3-week (100 mg/m 2 , 171 cases). The median follow-up duration was 85 months (range, 5-204 months). Overall and distant failure rates were observed in 27.1% (n = 55) and 13.8% (n = 28) patients, respectively. The 5-year locoregional recurrence-free survival (LRRFS), distant metastasis-free survival (DMFS), disease-free survival (DFS), and overall survival (OS) rates were 84.1%, 86.4%, 75%, and 78.7% respectively. The overall stage was an independent prognostic factor for the LRRFS, DMFS, DFS, and OS. The WHO histological type was a prognostic factor for the LRRFS, DFS, and OS. Age was a prognostic factor for the DMFS, DFS, and OS. Concurrent P schedule was independent prognostic only the LRRFS.</description><subject>Antineoplastic Combined Chemotherapy Protocols - adverse effects</subject><subject>Chemoradiotherapy</subject><subject>Cisplatin</subject><subject>concomitant chemoradiotherapy</subject><subject>docetaxel</subject><subject>Docetaxel - therapeutic use</subject><subject>Humans</subject><subject>Induction Chemotherapy</subject><subject>Kaplan-Meier Estimate</subject><subject>Nasopharyngeal carcinoma</subject><subject>Nasopharyngeal Carcinoma - drug therapy</subject><subject>Nasopharyngeal Carcinoma - etiology</subject><subject>Nasopharyngeal Neoplasms - drug therapy</subject><subject>Nasopharyngeal Neoplasms - pathology</subject><subject>Retrospective Studies</subject><issn>1120-009X</issn><issn>1973-9478</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNp9kMtuFDEQRS1ERKKQTwjykk1P_Oj2YwcaEUCKxAak7CyPXU0bdduN7VGYv49HM2GZVdXi3Fuqg9AtJRtKFLmjlBFC9OOGEcY3jNGBaPIGXVEtead7qd62vTHdEbpEN6X8aTwRTHIt3qFLLhmlSrArtGxDWWdbQ-x8clDtP5hxiH7vakgRuwmWVCfIdj3gMWW8NhRiLfgp1AlHW9I62XyIv8HO2NnsQkyLbQ3Y4phiB9HDEhx2aUq5vkcXo50L3JznNfp1_-Xn9lv38OPr9-3nh85x2tdO9F6DU8LpQTqrhPBUCMZGbonud15qzbSAHTjoHe-J136gOzZaq6hysif8Gn089a45_d1DqWYJxcE82whpXwxTVEqpCBsaOpxQl1MpGUaz5rC0lwwl5ijbvMg2R9nmLLvlPpxP7HcL-P-pF7UN-HQCQmziFvuU8uxNtYc55THb6EIx_PUbz4HokDg</recordid><startdate>202404</startdate><enddate>202404</enddate><creator>Özkaya Toraman, Kübra</creator><creator>Meral, Rasim</creator><creator>Karadeniz, Ahmet Nafiz</creator><creator>Kaval, Gizem</creator><creator>Başaran, Mert</creator><creator>Ekenel, Meltem</creator><creator>Altun, Musa</creator><general>Taylor &amp; Francis</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-0943-7287</orcidid><orcidid>https://orcid.org/0000-0003-1887-5561</orcidid><orcidid>https://orcid.org/0000-0003-2518-5980</orcidid><orcidid>https://orcid.org/0000-0002-6585-4598</orcidid><orcidid>https://orcid.org/0000-0003-1006-1942</orcidid><orcidid>https://orcid.org/0000-0001-5437-134X</orcidid><orcidid>https://orcid.org/0000-0002-4921-6975</orcidid></search><sort><creationdate>202404</creationdate><title>Cisplatin-docetaxel induction chemotherapy for patients with nasopharyngeal carcinoma in a non-endemic cohort</title><author>Özkaya Toraman, Kübra ; Meral, Rasim ; Karadeniz, Ahmet Nafiz ; Kaval, Gizem ; Başaran, Mert ; Ekenel, Meltem ; Altun, Musa</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c314t-64d9ec86c957ca866d16622f3a094bd799296ebece4c340d9d51b2faa818c7403</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Antineoplastic Combined Chemotherapy Protocols - adverse effects</topic><topic>Chemoradiotherapy</topic><topic>Cisplatin</topic><topic>concomitant chemoradiotherapy</topic><topic>docetaxel</topic><topic>Docetaxel - therapeutic use</topic><topic>Humans</topic><topic>Induction Chemotherapy</topic><topic>Kaplan-Meier Estimate</topic><topic>Nasopharyngeal carcinoma</topic><topic>Nasopharyngeal Carcinoma - drug therapy</topic><topic>Nasopharyngeal Carcinoma - etiology</topic><topic>Nasopharyngeal Neoplasms - drug therapy</topic><topic>Nasopharyngeal Neoplasms - pathology</topic><topic>Retrospective Studies</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Özkaya Toraman, Kübra</creatorcontrib><creatorcontrib>Meral, Rasim</creatorcontrib><creatorcontrib>Karadeniz, Ahmet Nafiz</creatorcontrib><creatorcontrib>Kaval, Gizem</creatorcontrib><creatorcontrib>Başaran, Mert</creatorcontrib><creatorcontrib>Ekenel, Meltem</creatorcontrib><creatorcontrib>Altun, Musa</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of chemotherapy (Florence)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Özkaya Toraman, Kübra</au><au>Meral, Rasim</au><au>Karadeniz, Ahmet Nafiz</au><au>Kaval, Gizem</au><au>Başaran, Mert</au><au>Ekenel, Meltem</au><au>Altun, Musa</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Cisplatin-docetaxel induction chemotherapy for patients with nasopharyngeal carcinoma in a non-endemic cohort</atitle><jtitle>Journal of chemotherapy (Florence)</jtitle><addtitle>J Chemother</addtitle><date>2024-04</date><risdate>2024</risdate><volume>ahead-of-print</volume><issue>ahead-of-print</issue><spage>1</spage><epage>10</epage><pages>1-10</pages><issn>1120-009X</issn><eissn>1973-9478</eissn><abstract>This is the report on our clinic's 15 years of experience (2004-2018) on nasopharyngeal carcinoma (NPC), treated with induction chemotherapy (IC) and subsequent concomitant chemoradiotherapy (CCRT), comprising population characteristics and treatment outcomes of 203 patients with non-metastatic NPC. IC comprised docetaxel (75 mg/m 2 ) and cisplatin (75 mg/m 2 ) combination (TP). Concurrent cisplatin (P) was applied either weekly (40 mg/m 2 , 32 cases) or every-3-week (100 mg/m 2 , 171 cases). The median follow-up duration was 85 months (range, 5-204 months). Overall and distant failure rates were observed in 27.1% (n = 55) and 13.8% (n = 28) patients, respectively. The 5-year locoregional recurrence-free survival (LRRFS), distant metastasis-free survival (DMFS), disease-free survival (DFS), and overall survival (OS) rates were 84.1%, 86.4%, 75%, and 78.7% respectively. The overall stage was an independent prognostic factor for the LRRFS, DMFS, DFS, and OS. The WHO histological type was a prognostic factor for the LRRFS, DFS, and OS. Age was a prognostic factor for the DMFS, DFS, and OS. Concurrent P schedule was independent prognostic only the LRRFS.</abstract><cop>England</cop><pub>Taylor &amp; Francis</pub><pmid>37211862</pmid><doi>10.1080/1120009X.2023.2215090</doi><tpages>10</tpages><orcidid>https://orcid.org/0000-0003-0943-7287</orcidid><orcidid>https://orcid.org/0000-0003-1887-5561</orcidid><orcidid>https://orcid.org/0000-0003-2518-5980</orcidid><orcidid>https://orcid.org/0000-0002-6585-4598</orcidid><orcidid>https://orcid.org/0000-0003-1006-1942</orcidid><orcidid>https://orcid.org/0000-0001-5437-134X</orcidid><orcidid>https://orcid.org/0000-0002-4921-6975</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 1120-009X
ispartof Journal of chemotherapy (Florence), 2024-04, Vol.ahead-of-print (ahead-of-print), p.1-10
issn 1120-009X
1973-9478
language eng
recordid cdi_proquest_miscellaneous_2817778025
source Taylor and Francis:Jisc Collections:Taylor and Francis Read and Publish Agreement 2024-2025:Medical Collection (Reading list)
subjects Antineoplastic Combined Chemotherapy Protocols - adverse effects
Chemoradiotherapy
Cisplatin
concomitant chemoradiotherapy
docetaxel
Docetaxel - therapeutic use
Humans
Induction Chemotherapy
Kaplan-Meier Estimate
Nasopharyngeal carcinoma
Nasopharyngeal Carcinoma - drug therapy
Nasopharyngeal Carcinoma - etiology
Nasopharyngeal Neoplasms - drug therapy
Nasopharyngeal Neoplasms - pathology
Retrospective Studies
title Cisplatin-docetaxel induction chemotherapy for patients with nasopharyngeal carcinoma in a non-endemic cohort
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-01T19%3A56%3A11IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_infor&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Cisplatin-docetaxel%20induction%20chemotherapy%20for%20patients%20with%20nasopharyngeal%20carcinoma%20in%20a%20non-endemic%20cohort&rft.jtitle=Journal%20of%20chemotherapy%20(Florence)&rft.au=%C3%96zkaya%20Toraman,%20K%C3%BCbra&rft.date=2024-04&rft.volume=ahead-of-print&rft.issue=ahead-of-print&rft.spage=1&rft.epage=10&rft.pages=1-10&rft.issn=1120-009X&rft.eissn=1973-9478&rft_id=info:doi/10.1080/1120009X.2023.2215090&rft_dat=%3Cproquest_infor%3E2817778025%3C/proquest_infor%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c314t-64d9ec86c957ca866d16622f3a094bd799296ebece4c340d9d51b2faa818c7403%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2817778025&rft_id=info:pmid/37211862&rfr_iscdi=true